home All News open_in_new Full Article

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it received a written notification from the Listing […]


today last month attach_file Economics

attach_file Economics
attach_file Other
attach_file Society
attach_file Other
attach_file Sport
attach_file Economics


ID: 514296744
Add Watch Country

arrow_drop_down